Anti-CDKN2A/p14ARF antibody (ab3642)
- Datasheet
- References (13)
- Protocols
Overview
-
Product nameAnti-CDKN2A/p14ARF antibody
See all CDKN2A/p14ARF primary antibodies -
DescriptionRabbit polyclonal to CDKN2A/p14ARF
-
Host speciesRabbit
-
Tested applicationsSuitable for: IHC-P, IHC-Fr, WB, ICC/IFmore details
-
Species reactivityReacts with: Human
-
Positive control
- Hela cells. Lymphoma This antibody gave a positive result when used in the following formaldehyde fixed cell lines: HeLa.
Properties
-
FormLiquid
-
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
-
Storage bufferpH: 7.40
Preservative: 0.1% Sodium azide
Constituents: 0.0268% PBS, 1% BSA -
Concentration information loading... -
PurityProtein A purified
-
ClonalityPolyclonal
-
IsotypeIgG
-
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
Applications
Our Abpromise guarantee covers the use of ab3642 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| IHC-P | 1/25. Perform heat mediated antigen retrieval before commencing with IHC staining protocol. | |
| IHC-Fr | Use at an assay dependent concentration. | |
| WB | Use a concentration of 1 - 2 µg/ml. Detects a band of approximately 14 kDa (predicted molecular weight: 14 kDa). | |
| ICC/IF | Use a concentration of 1 µg/ml. |
Target
-
RelevanceThe gene for CDK2NA generates several transcripts/proteins which differ from each other in their first exons. Three of these transcripts are generated by alternative splicing (isoform 1 a.k.a p16INK4A, isoform 2 and isoform 3 a.k.a p12), two of which are known to function as inhibitors of CDK4 kinase. One other transcript that is generated from this gene contains an alternate reading frame (ARF), with the first exon located 20kb upstream of the remainder of the gene(isoform 4 a.k.a. p14ARF, p19ARF, ARF). In spite of the structural and some functional differences, all the proteins encoded by the CDKN2A gene are involved in cell cycle G1 control.
-
Cellular localizationCytoplasmic and Nuclear
-
Database links
- Entrez Gene: 1029 Human
- Omim: 600160 Human
- SwissProt: P42771 Human
- SwissProt: Q8N726 Human
- Unigene: 512599 Human
-
Alternative names
- ARF antibody
- CDK4 inhibitor p16 INK4 antibody
- CDK4I antibody
see all
Images
-
Immunocytochemistry/ Immunofluorescence - Anti-CDKN2A/p14ARF antibody (ab3642)Confocal image showing nuclear staining increased after HeLa cells transfected with CDKN2A/p14ARF.
ICC/IF image of ab3642 stained HeLa cells. The cells were 4% paraformaldehyde fixed and then incubated in 0.1% trixtonX-100 to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with primary antibody ab3642 at a dilution of 1/250. An AlexaFluor®594 goat anti-mouse secondary IgG (ab150077) was used at a 1/1000 dilution. Anti-tubulin (ab7291) and an AlexaFluor®594 goat anti-mouse IgG (ab150120) were used as counterstains, both at a dilution of 1/1000. DAPI was used to stain the cell nuclei blue.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CDKN2A/p14ARF antibody (ab3642)This image was kindly supplied as part of the review submitted by Joost van Galen. -
Immunocytochemistry/ Immunofluorescence - Anti-CDKN2A/p14ARF antibody (ab3642)ICC/IF image of ab3642 stained HeLa cells. The cells were 4% formaldehyde fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody ab3642 at 1µg/ml overnight at +4°C. The secondary antibody (green) was DyLight® 488 goat anti- rabbit (ab96899) IgG (H+L) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
Protocols
References
This product has been referenced in:
- Liang J et al. CDKN2A inhibits formation of homotypic cell-in-cell structures. Oncogenesis 7:50 (2018). Read more (PubMed: 29904067) »
- Xie H & Wang H PRL-3 promotes breast cancer progression by downregulating p14ARF-mediated p53 expression. Oncol Lett 15:2795-2800 (2018). Read more (PubMed: 29435006) »
